Amylyx Pharmaceuticals Ends PSP Trial of AMX0035

Amylyx Pharmaceuticals announced recently that it would end its phase 2b trial of its drug AMX0035 for the treatment of progressive supranuclear palsy (PSP). The trial will not proceed to phase 3 due to a lack of impact of the drug on…